Superiority of deformable image co-registration in the integration of diagnostic positron emission tomography-computed tomography to the radiotherapy treatment planning pathway for oesophageal carcinoma

Article English OPEN
Ward, G.; Ramasamy, S.; Sykes, J.R.; Prestwich, R.; Chowdhury, F.; Scarsbrook, A.; Murray, P.; Harris, K.; Crellin, A.; Hatfield, P.; Sebag-Montefiore, D.; Spezi, Emiliano; Crosby, T.; Radhakrishna, G.;

Aims\ud To investigate the use of image co-registration in incorporating diagnostic positron emission tomography-computed tomography (PET-CT) directly into the radiotherapy treatment planning pathway, and to describe the pattern of local recurrence relative to the PET-a... View more
  • References (37)
    37 references, page 1 of 4

    1. Cancer Research UK, One-, five- and ten-year survival for oesophageal cancer [] Accessed November 2015

    2. Button MR, Morgan CA, Croydon ES, Roberts SA & Crosby TDL. Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009; 73(3): 818-823.

    3. Muijs CT, Beukema JC, Woutersen D, Mul VE, Berveling MJ, Pruim J et al. Clinical validation of FDG-PET/CT in the radiation treatment planning for patients with oesophageal cancer. Radiother Oncol 2014; 113: 188-192

    4. Muijs C, Smit J, Karrenbeld A, Beuhema J, Mul V, van Damn G, et al. Residual Tumor After Neoadjuvant Chemoradiation Outside the Radiation Therapy Target Volume: A New Prognostic Factor for Survival in Esophageal Cancer. Int J Radiat Oncol Biol Phys 2014; 88(4): 845-852

    5. Muijs CT, Beukema JC, Pruim J, Mul VE, Groen H, Plukker JT et al. A systematic review on the role of FDG-PET-CT in tumour delineation and radiotherapy planning in patients with esophageal cancer. Radiat Oncol 2010; 97: 165-171.

    6. Konski A., Doss M., Milestone B., Haluszka O., Hanlon A., Freedman G et al. The integration of 18-Fluoro-deoxy-glucose position emission tomography and endoscopic ultrasound in the treatment planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys 2005; 61(4): 1123-1128.

    7. Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 2005; 63(4): 1053-1059.

    8. Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC and Blake MA. Adenocarcinomas of the esophagus: Response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol 2009; 89: 278-286.

    9. Muijs CT, Schreurs LM, Busz DM, Beukema JC, van der Borden AJ, Pruim J et al. Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer. Radiot Oncol 2009; 93: 447-453.

    10. Jayachandran P, Reetesh KP, Quon A, Graves E, Krakow TE, La T et al. Postchemoradiotherapy Positron Emission Tomography predicts pathologic response and survival in patients with esophageal cancer. Int J Radiat Oncol Biol Phys 2012; 84(2): 471- 477.

  • Similar Research Results (2)
  • Metrics
Share - Bookmark